Tag: type2Diabetes

Articles

• Influence of BMI, metabolic syndrome and diabetes on TN prognosis
• Obesity increases risk of breast cancer and worsens prognosis
• Type 2 diabetes increases breast cancer risk

News

06/09/22

Breast cancer cells increase access to glucose by interfering with insulin production

05/06/19

Metformin reduces resistance to Adriamycin chemotherapy

10/08/17

Use of metformin linked to lower recurrence among older BC survivors

02/21/16

HDL from BC patients with type 2 diabetes can promote metastasis

03/22/15

Type 2 diabetes is linked to higher breast cancer stage at diagnosis

10/31/13

Poor glucose control could reduce metformin's anti-cancer benefits

04/28/13

High circulating insulin increases HER2+ tumor size and metastases

12/13/11

Metformin improves survival of diabetic women with HER2+ BC

11/18/11

Metformin may increase the effectiveness of radiation treatment

Studies

• Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions Cite
  Sekar AP, Nurmala S, Matsuura E, Tan XW, Rahmasari R, Sauriasari R. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2024; 18 10.1177/11782234241240173
• Associations between diabetes and cancer: A 10-year national population-based retrospective cohort study Cite
  Safadi H, Balogh Á, Lám J, Nagy A, Belicza É. Associations between diabetes and cancer: A 10-year national population-based retrospective cohort study. Diabetes Research and Clinical Practice. Elsevier BV; 2024;:111665 10.1016/j.diabres.2024.111665
• Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants Cite
  Jenkins DJA, Willett WC, Yusuf S, Hu FB, Glenn AJ, Liu S, et al. Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants. The Lancet Diabetes & Endocrinology. Elsevier BV; 2024; 12:107-118 10.1016/s2213-8587(23)00344-3
• Antidiabetic Drugs in Breast Cancer Patients Cite
  Garczorz W, Kosowska A, Francuz T. Antidiabetic Drugs in Breast Cancer Patients. Cancers. MDPI AG; 2024; 16:299 10.3390/cancers16020299
• Ultra‐processed food and non‐communicable diseases in the United Kingdom: A narrative review and thematic synthesis of literature Cite
  Henney AE, Gillespie CS, Alam U, Hydes TJ, Boyland E, Cuthbertson DJ. Ultra‐processed food and non‐communicable diseases in the United Kingdom: A narrative review and thematic synthesis of literature. Obesity Reviews. Wiley; 2024; 10.1111/obr.13682
• Association between prediabetes and breast cancer: a comprehensive meta-analysis Cite
  Keesari PR, Jain A, Ganampet NR, Subhasri GSD, Edusa S, Muslehuddin Z, et al. Association between prediabetes and breast cancer: a comprehensive meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07181-x
• Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study Cite
  Peila R, Rohan TE. Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study. International Journal of Cancer. Wiley; 2023; 10.1002/ijc.34795
• New Insights into Prospective Health Potential of ω-3 PUFAs Cite
  Lakshimi VI, Kavitha M. New Insights into Prospective Health Potential of ω-3 PUFAs. Current Nutrition Reports. Springer Science and Business Media LLC; 2023; 10.1007/s13668-023-00508-6
• Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy Cite
  Thomas NS, Scalzo RL, Wellberg EA. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nature Reviews Endocrinology. Springer Science and Business Media LLC; 2023; 10.1038/s41574-023-00899-0
• Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer Cite
  Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.23.00296
• Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis Cite
  Jordt N, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D. Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07043-6
• Açai Berry Ameliorates Cognitive Impairment by Inhibiting NLRP3/ASC/CASP axis in STZ-Induced Diabetic Neuropathy in Mice Cite
  Impellizzeri D, Siracusa R, D'Amico R, Fusco R, Cordaro M, Cuzzocrea S, et al. Açai Berry Ameliorates Cognitive Impairment by Inhibiting NLRP3/ASC/CASP axis in STZ-Induced Diabetic Neuropathy in Mice. Journal of Neurophysiology. American Physiological Society; 2023; 10.1152/jn.00239.2023
• Metformin combined with glucose starvation synergistically suppress triple-negative breast cancer by enhanced unfolded protein response Cite
  Li Y, Zhang Q, Yang J, He W, Jiang Y, Chen Y, et al. Metformin combined with glucose starvation synergistically suppress triple-negative breast cancer by enhanced unfolded protein response. Biochemical and Biophysical Research Communications. Elsevier BV; 2023; 10.1016/j.bbrc.2023.07.029
• Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study Cite
  Xiong F, Wang J, Nierenberg JL, Van Blarigan EL, Kenfield SA, Chan JM, et al. Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-023-02345-4
• Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study Cite
  Shi Y, Qiu Z, Yu J, Li Z, Hua S, Chen Y, et al. Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11102-y
• Insulin resistance in patients with cancer: a systematic review and meta-analysis Cite
  Màrmol JM, Carlsson M, Raun SH, Grand MK, Sørensen J, Lang Lehrskov L, et al. Insulin resistance in patients with cancer: a systematic review and meta-analysis. Acta Oncologica. Informa UK Limited; 2023; 62:364-371 10.1080/0284186x.2023.2197124
• Does insulin make breast cancer cells resistant to doxorubicin toxicity? Cite
  Lykhova O, Zavelevich M, Philchenkov A, Vidasov N, Kozak T, Lozovska Y, et al. Does insulin make breast cancer cells resistant to doxorubicin toxicity?. Naunyn-Schmiedeberg's Archives of Pharmacology. Springer Science and Business Media LLC; 2023; 10.1007/s00210-023-02516-3
• Cancer incidence and mortality in 23,000 patients with type 1 diabetes in the UK: Long‐term follow‐up Cite
  Swerdlow AJ, Jones ME, Slater SD, Burden ACF, Botha JL, Waugh NR, et al. Cancer incidence and mortality in 23,000 patients with type 1 diabetes in the UK: Long‐term follow‐up. International Journal of Cancer. Wiley; 2023; 10.1002/ijc.34548
• Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition Cite
  Mahamat‐Saleh Y, Rinaldi S, Kaaks R, Biessy C, Gonzalez‐Gil EM, Murphy N, et al. Metabolically defined body size and body shape phenotypes and risk of postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Medicine. Wiley; 2023; 10.1002/cam4.5896
• Targeting Breast Cancer in Diabetic Mice Using a Combination of Thymoquinone and Metformin Cite
  Talib WH, Aboulqassim NSS. Targeting Breast Cancer in Diabetic Mice Using a Combination of Thymoquinone and Metformin. The Natural Products Journal. Bentham Science Publishers Ltd.; 2023; 13 10.2174/2210315512666220615114025
• Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications Cite
  Bashraheel SS, Kheraldine H, Khalaf S, Moustafa AA. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. Biomedicine & Pharmacotherapy. Elsevier BV; 2023; 162:114676 10.1016/j.biopha.2023.114676
• Hyperglycemia induces PFKFB3 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK activation Cite
  Cheng X, Jia X, Wang C, Zhou S, Chen J, Chen L, et al. Hyperglycemia induces PFKFB3 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK activation. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2023; 21 10.1186/s12957-023-02990-2
• Metformin and long non-coding RNAs in breast cancer Cite
  Gholami M, Klashami ZN, Ebrahimi P, Mahboobipour AA, Farid AS, Vahidi A, et al. Metformin and long non-coding RNAs in breast cancer. Journal of Translational Medicine. Springer Science and Business Media LLC; 2023; 21 10.1186/s12967-023-03909-x
• Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study Cite
  Castro-Espin C, Bonet C, Crous-Bou M, Katzke V, Le Cornet C, Jannasch F, et al. Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-023-02169-2
• Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus Cite
  Zhang F, de Bock GH, Denig P, Landman GW, Zhang Q, Sidorenkov G. Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus. Clinical Epidemiology. Informa UK Limited; 2023; Volume 15:109-121 10.2147/clep.s386471
• Aspirin and Risk of Specific Breast Cancer Subtype in Women with Diabetes Cite
  Yang Y, Kornelius E, Lo S, Wang Y, Huang C. Aspirin and Risk of Specific Breast Cancer Subtype in Women with Diabetes. Journal of Women's Health. Mary Ann Liebert Inc; 2023; 10.1089/jwh.2022.0055
• Metabolic abnormalities and survival among patients with non-metastatic breast cancer Cite
  Zimbalist AS, Caan BJ, Chen WY, Mittendorf EA, Dillon DAR, Quesenberry C, et al. Metabolic abnormalities and survival among patients with non-metastatic breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2022; 22 10.1186/s12885-022-10430-9
• Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes Cite
  Chikermane SG, Sharma M, Abughosh SM, Aparasu RR, Trivedi MV, Johnson ML. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06706-0
• Exposure to Endocrine-Disrupting Chemicals and Type 2 Diabetes Mellitus in Later Life Cite
  Lin J, Yin R. Exposure to Endocrine-Disrupting Chemicals and Type 2 Diabetes Mellitus in Later Life. Exposure and Health. Springer Science and Business Media LLC; 2022; 10.1007/s12403-022-00486-0
• Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study Cite
  Sylow L, Grand MK, von Heymann A, Persson F, Siersma V, Kriegbaum M, et al. Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study. Diabetes Care. American Diabetes Association; 2022; 45:e105-e106 10.2337/dc22-0232
• Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells Cite
  Scordamaglia D, Cirillo F, Talia M, Santolla MF, Rigiracciolo DC, Muglia L, et al. Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. Journal of Translational Medicine. Springer Science and Business Media LLC; 2022; 20 10.1186/s12967-022-03463-y
• Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth Cite
  Cao M, Isaac R, Yan W, Ruan X, Jiang L, Wan Y, et al. Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. Nature Cell Biology. Springer Science and Business Media LLC; 2022; 10.1038/s41556-022-00919-7
• Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer Cite
  Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA. American Medical Association (AMA); 2022; 327:1963 10.1001/jama.2022.6147
• Impact of Diabetes on Patient Outcomes in Breast Cancer Patients Cite
  Tobe A, Horimoto Y, Kobayashi K, Kamisada N, Hirano M. Impact of Diabetes on Patient Outcomes in Breast Cancer Patients. Breast Care. S. Karger AG; 2022; 10.1159/000524513
• The influence of metabolic factors and ethnicity on breast cancer risk, treatment and survival: The Oslo ethnic breast cancer study Cite
  Lofterød T, Frydenberg H, Veierød MB, Jenum AK, Reitan JB, Wist EA, et al. The influence of metabolic factors and ethnicity on breast cancer risk, treatment and survival: The Oslo ethnic breast cancer study. Acta Oncologica. Informa UK Limited; 2022;:1-9 10.1080/0284186x.2022.2053573
• Abstract P4-11-33: Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer Cite
  Accordino MK, Spivack JH, Ulene S, Honan E, Trivedi MS, Crew KD, et al. Abstract P4-11-33: Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P4-11-33-P4-11-33 10.1158/1538-7445.sabcs21-p4-11-33
• Dietary Intake of Polyphenols or Polyunsaturated Fatty Acids and Its Relationship with Metabolic and Inflammatory State in Patients with Type 2 Diabetes Mellitus Cite
  Kosmalski M, Pękala-Wojciechowska A, Sut A, Pietras T, Luzak B. Dietary Intake of Polyphenols or Polyunsaturated Fatty Acids and Its Relationship with Metabolic and Inflammatory State in Patients with Type 2 Diabetes Mellitus. Nutrients. MDPI AG; 2022; 14:1083 10.3390/nu14051083
• Metformin and Breast Cancer: Where Are We Now? Cite
  Cejuela M, Martin-Castillo B, Menendez JA, Pernas S. Metformin and Breast Cancer: Where Are We Now?. International Journal of Molecular Sciences. MDPI AG; 2022; 23:2705 10.3390/ijms23052705
• Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Cite
  Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP, et al. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. Gynecologic Oncology. Elsevier BV; 2022; 10.1016/j.ygyno.2022.01.022
• A Low-Glucose Eating Pattern Improves Biomarkers of Postmenopausal Breast Cancer Risk: An Exploratory Secondary Analysis of a Randomized Feasibility Trial Cite
  Schembre SM, Jospe MR, Giles ED, Sears DD, Liao Y, Basen-Engquist KM, et al. A Low-Glucose Eating Pattern Improves Biomarkers of Postmenopausal Breast Cancer Risk: An Exploratory Secondary Analysis of a Randomized Feasibility Trial. Nutrients. MDPI AG; 2021; 13:4508 10.3390/nu13124508
• Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study Cite
  Sjöholm K, Carlsson LM, Svensson P, Andersson-Assarsson JC, Kristensson F, Jacobson P, et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care. American Diabetes Association; 2021;:dc211335 10.2337/dc21-1335
• Effects of red raspberry polyphenols and metabolites on biomarkers of inflammation and insulin resistance in type 2 diabetes: A pilot study Cite
  Moreno RU, Gonzalez-Sarrias A, Espin JC, Tomas-Barberan F, Janes ME, Cheng H, et al. Effects of red raspberry polyphenols and metabolites on biomarkers of inflammation and insulin resistance in type 2 diabetes: A pilot study. Food & Function. Royal Society of Chemistry (RSC); 2022; 10.1039/d1fo02090k
• Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes Cite
  Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, et al. Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes. Science Signaling. American Association for the Advancement of Science (AAAS); 2021; 14 10.1126/scisignal.abj2807
• Type 2 Diabetes and all-cause mortality among Spanish women with breast cancer Cite
  Fernández-Arce L, Robles-Rodríguez N, Fernández-Feito A, Llaneza-Folgueras A, Encinas-Muñiz AI, Lana A. Type 2 Diabetes and all-cause mortality among Spanish women with breast cancer. Cancer Causes & Control. Springer Science and Business Media LLC; 2021; 10.1007/s10552-021-01526-x
• Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: analysis of the MEND study Cite
  Akinyemiju T, Oyekunle T, Salako O, Gupta A, Alatise O, Ogun G, et al. Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: analysis of the MEND study. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.11.004
• Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells Cite
  Vella V, Giuliano M, La Ferlita A, Pellegrino M, Gaudenzi G, Alaimo S, et al. Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells. Cells. MDPI AG; 2021; 10:3145 10.3390/cells10113145
• Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance Cite
  Lam BQ, Srivastava R, Morvant J, Shankar S, Srivastava RK. Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance. Cells. MDPI AG; 2021; 10:3077 10.3390/cells10113077
• Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells Cite
  Tully E, Bharti S, Woo J, Bhujwalla Z, Gabrielson E. Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells. Cancer Biology & Therapy. Informa UK Limited; 2021;:1-8 10.1080/15384047.2021.1982599
• Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs Cite
  Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell International. Springer Science and Business Media LLC; 2021; 21 10.1186/s12935-021-02202-5
• Hyperglycemic conditions proliferate triple negative breast cancer cells: role of ornithine decarboxylase Cite
  Capellen CC, Ortega-Rodas J, Morwitzer MJ, Tofilau HMN, Dunworth M, Casero RA, et al. Hyperglycemic conditions proliferate triple negative breast cancer cells: role of ornithine decarboxylase. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06388-0
• Adhesion and Stiffness of Detached Breast Cancer Cells In Vitro: Co-Treatment with Metformin and 2-Deoxy-d-glucose Induces Changes Related to Increased Metastatic Potential Cite
  Zemljič-Jokhadar Š, Kokot G, Pavlin M, Derganc J. Adhesion and Stiffness of Detached Breast Cancer Cells In Vitro: Co-Treatment with Metformin and 2-Deoxy-d-glucose Induces Changes Related to Increased Metastatic Potential. Biology. MDPI AG; 2021; 10:873 10.3390/biology10090873
• Egg Consumption in the Context of Plant-Based Diets and Cardiometabolic Risk Factors in Adults at Risk of Type 2 Diabetes Cite
  Njike VY, Treu JA, Kela GCM, Ayettey RG, Comerford BP, Siddiqui WT. Egg Consumption in the Context of Plant-Based Diets and Cardiometabolic Risk Factors in Adults at Risk of Type 2 Diabetes. The Journal of Nutrition. Oxford University Press (OUP); 2021; 10.1093/jn/nxab283
• Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside? Cite
  Marini C, Cossu V, Bauckneht M, Lanfranchi F, Raffa S, Orengo AM, et al. Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?. Biomolecules. MDPI AG; 2021; 11:1231 10.3390/biom11081231
• Glucose stress induces early onset of metastasis in hormone-sensitive breast cancer cells. Cite
  Aftab S, Shakoori AR. Glucose stress induces early onset of metastasis in hormone-sensitive breast cancer cells.. Critical Reviews in Eukaryotic Gene Expression. Begell House; 2021; 10.1615/critreveukaryotgeneexpr.2021039789
• The influence of hormone therapy on secondary diabetes mellitus in breast cancer: a meta-analysis Cite
  Ye F, Wen J, Yang A, Wang Y, Li N, Yu P, et al. The influence of hormone therapy on secondary diabetes mellitus in breast cancer: a meta-analysis. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.06.014
• The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32 Cite
  Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, et al. The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 113:192-198 10.1093/jnci/djaa082
• Diabetes Risk Reduction Diet and Survival After Breast Cancer Diagnosis Cite
  Wang T, Farvid MS, Kang JH, Holmes MD, Rosner BA, Tamimi RM, et al. Diabetes Risk Reduction Diet and Survival After Breast Cancer Diagnosis. Cancer Research. American Association for Cancer Research (AACR); 2021;:canres.0256.2021 10.1158/0008-5472.can-21-0256
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Hautakoski A, Marttila M, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-88488-x
• Impact of insulin use on outcomes of diabetic breast cancer patients: a systematic review and meta-analysis Cite
  Wang L, Zhang H, Liu Y, Chen G. Impact of insulin use on outcomes of diabetic breast cancer patients: a systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences. Verduci Editore s.r.l.; 2021; 25:3507-3518. 10.26355/eurrev_202105_25833
• Incident Type 2 Diabetes Duration and Cancer Risk: A Prospective Study in Two US Cohorts Cite
  Hu Y, Zhang X, Ma Y, Yuan C, Wang M, Wu K, et al. Incident Type 2 Diabetes Duration and Cancer Risk: A Prospective Study in Two US Cohorts. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 113:381-389 10.1093/jnci/djaa141
• Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study Cite
  Feng J, Qin X. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study. Diabetes Research and Clinical Practice. Elsevier BV; 2021;:108755 10.1016/j.diabres.2021.108755
• Abstract GS2-09: Diabetes risk reduction diet and survival following breast cancer Cite
  Wang T, Farvid M, Kang JH, Holmes M, Rosner B, Tamimi R, et al. Abstract GS2-09: Diabetes risk reduction diet and survival following breast cancer. General Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-gs2-09
• A prospective study of type 2 diabetes, metformin use, and risk of breast cancer Cite
  Park Y, Bookwalter D, O'Brien K, Jackson C, Weinberg C, Sandler D. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Annals of Oncology. Elsevier BV; 2021; 10.1016/j.annonc.2020.12.008
• Metabolic syndrome risk components and mortality after triple‐negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative Cite
  Yuan Y, Pan K, Mortimer J, Chlebowski RT, Luo J, Yan JE, et al. Metabolic syndrome risk components and mortality after triple‐negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer. Wiley; 2021; 10.1002/cncr.33407
• Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population? Cite
  Kennard K, Buckley ME, Sizer LM, Larson S, Carter WB, Frazier TG, et al. Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-020-06034-1
• Breast cancer risk factors and their effects on survival: a Mendelian randomisation study Cite
  Escala-Garcia M, Morra A, Canisius S, Chang-Claude J, Kar S, Zheng W, et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC Medicine. Springer Science and Business Media LLC; 2020; 18 10.1186/s12916-020-01797-2
• Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity Cite
  Dahmani Z, Addou-Klouche L, Gizard F, Dahou S, Messaoud A, Chahinez Djebri N, et al. Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0240982 10.1371/journal.pone.0240982
• High-sensitivity C-reactive protein, hemoglobin A1c and breast cancer risk: a nested case–control study from Alberta’s Tomorrow Project cohort Cite
  Price TR, Friedenreich CM, Robson PJ, Li H, Brenner DR. High-sensitivity C-reactive protein, hemoglobin A1c and breast cancer risk: a nested case–control study from Alberta’s Tomorrow Project cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2020; 31:1057-1068 10.1007/s10552-020-01329-6
• Use of metformin and aspirin is associated with delayed cancer incidence Cite
  Sung JJ, Ho JM, Lam AS, Yau ST, Tsoi KK. Use of metformin and aspirin is associated with delayed cancer incidence. Cancer Epidemiology. Elsevier BV; 2020; 69:101808 10.1016/j.canep.2020.101808
• Patterns of cell death induced by metformin in human MCF-7 breast cancer cells Cite
  Dias Lopes NM, Marinello PC, Sanches LJ, da Silva Brito WA, Lovo-Martins MI, Pinge-Filho P, et al. Patterns of cell death induced by metformin in human MCF-7 breast cancer cells. Pathology - Research and Practice. Elsevier BV; 2020; 216:153199 10.1016/j.prp.2020.153199
• Effects of metformin on adipose-derived stromal cell (ADSC) – Breast cancer cell lines interaction Cite
  Teufelsbauer M, Rath B, Plangger A, Staud C, Nanobashvili J, Huk I, et al. Effects of metformin on adipose-derived stromal cell (ADSC) – Breast cancer cell lines interaction. Life Sciences. Elsevier BV; 2020; 261:118371 10.1016/j.lfs.2020.118371
• Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis Cite
  Marinello PC, Panis C, Silva TN, Binato R, Abdelhay E, Rodrigues JA, et al. Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. Pathology - Research and Practice. Elsevier BV; 2020; 216:153135 10.1016/j.prp.2020.153135
• Influences of preoperative metformin on immunological factors in early breast cancer Cite
  Tsukioki T, Shien T, Tanaka T, Suzuki Y, Kajihara Y, Hatono M, et al. Influences of preoperative metformin on immunological factors in early breast cancer. Cancer Chemotherapy and Pharmacology. Springer Science and Business Media LLC; 2020; 86:55-63 10.1007/s00280-020-04092-2
• Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative Cite
  Pan K, Chlebowski RT, Mortimer JE, Gunther MJ, Rohan T, Vitolins MZ, et al. Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative. Cancer. Wiley; 2020; 126:3638-3647 10.1002/cncr.33002
• Insulin resistance contributes to racial disparities in breast cancer prognosis in US women Cite
  Gallagher EJ, Fei K, Feldman SM, Port E, Friedman NB, Boolbol SK, et al. Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01281-y
• Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study Cite
  Sundelin EIO, al-Suliman N, Vahl P, Vendelbo M, Munk OL, Jakobsen S, et al. Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:107-113 10.1007/s10549-020-05621-6
• History of Diabetes Mellitus and Risk of Breast Cancer in Asian Women: A Meta-Epidemiological Analysis of Population-Based Cohort Studies Cite
  Bae J. History of Diabetes Mellitus and Risk of Breast Cancer in Asian Women: A Meta-Epidemiological Analysis of Population-Based Cohort Studies. Journal of Menopausal Medicine. The Korean Society of Menopause; 2020; 26:29 10.6118/jmm.19014
• Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients Cite
  Tharakan S, Zimmerman B, Ru M, Blanter J, Cascetta K, Tiersten A. Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. Oncology. S. Karger AG; 2020; 98:589-592 10.1159/000506076
• The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes Cite
  Min W, Wang B, Guo A, Mao G, Zhao Y, Zhang S, et al. The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes. World Journal of Oncology. Elmer Press, Inc.; 2020; 11:23-32 10.14740/wjon1242
• Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response Cite
  Hassinger TE, Berger AC, Christopher A, Knisely AT, Mehaffey JH, Brenin DR, et al. Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. Journal of Surgical Research. Elsevier BV; 2020; 247:52-58 10.1016/j.jss.2019.10.043
• Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer Cite
  Chen H, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2019; 28:1802-1808 10.1158/1055-9965.epi-19-0291
• Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes Cite
  Li N, Lv X, Wang X, Wang R, Huang Y. Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes. Breast Cancer. Springer Science and Business Media LLC; 2019; 26:712-718 10.1007/s12282-019-00976-1
• Diabetes, obesity, and subsequent risk of postmenopausal breast cancer among white and black women in the Southern Community Cohort Study Cite
  Sanderson M, Lipworth L, Shrubsole MJ, Andersen SW, Shu X, Zheng W, et al. Diabetes, obesity, and subsequent risk of postmenopausal breast cancer among white and black women in the Southern Community Cohort Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2019; 30:425-433 10.1007/s10552-019-01164-4
• Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes Cite
  Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Scientific Reports. Springer Science and Business Media LLC; 2019; 9 10.1038/s41598-019-42357-w
• Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy Cite
  Lee A, Jo S, Lee C, Shin H, Kim TH, Ahn KJ, et al. Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy. Breast Cancer. Springer Science and Business Media LLC; 2019; 26:672-680 10.1007/s12282-019-00967-2
• Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:741-748 10.1007/s10549-019-05185-0
• Abstract P1-10-02: Type II diabetes and subtype-specific breast cancer risk in medically underserved black and white women Cite
  Gross A, Blot W, Visvanathan K. Abstract P1-10-02: Type II diabetes and subtype-specific breast cancer risk in medically underserved black and white women. Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p1-10-02
• Fructosamine and diabetes as predictors of mortality among Hispanic and non-Hispanic white breast cancer survivors Cite
  Connor AE, Visvanathan K, Boone SD, Rifai N, Baumgartner KB, Baumgartner RN. Fructosamine and diabetes as predictors of mortality among Hispanic and non-Hispanic white breast cancer survivors. npj Breast Cancer. Springer Science and Business Media LLC; 2019; 5 10.1038/s41523-018-0099-x
• Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells Cite
  Schexnayder C, Broussard K, Onuaguluchi D, Poché A, Ismail M, McAtee L, et al. Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. International Journal of Molecular Sciences. MDPI AG; 2018; 19:3692 10.3390/ijms19113692
• Type 2 diabetes as a predictor of survival among breast cancer patients: the multiethnic cohort Cite
  Maskarinec G, Shvetsov YB, Conroy SM, Haiman CA, Setiawan VW, Le Marchand L. Type 2 diabetes as a predictor of survival among breast cancer patients: the multiethnic cohort. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 173:637-645 10.1007/s10549-018-5025-2
• Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study Cite
  Borgquist S, Rosendahl AH, Czene K, Bhoo-Pathy N, Dorkhan M, Hall P, et al. Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study. Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-1026-7
• Abstract B76: High glucose induces breast cancer progression through upregulating PP2Cδ Cite
  Wu K, Yu X, Yi X, Ma L, Elshimali Y, Liu Y, et al. Abstract B76: High glucose induces breast cancer progression through upregulating PP2Cδ. Cell, Molecular, and Tumor Biology. American Association for Cancer Research; 2018; 10.1158/1538-7755.disp17-b76
• Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer Cite
  Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-0974-2
• Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer Cite
  Alaswad RS W, SM E, HS S, AD T. Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. Journal of Oncology Translational Research. OMICS Publishing Group; 2018; 04 10.4172/2476-2261.1000129
• Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization Cite
  Wang J, Sun X, Ma Q, Fu G, Cong L, Zhang H, et al. Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. Journal of Cellular and Molecular Medicine. Wiley; 2018; 22:3825-3836 10.1111/jcmm.13655
• Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study Cite
  Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:2061-2069 10.1200/jco.2017.76.3524
• Abstract P6-10-03: The association between type-2 diabetes and risk of mortality after invasive breast cancer among Hispanic and non-Hispanic white women from New Mexico Cite
  Connor A, Visvanathan K, Boone S, Baumgartner K, Baumgartner R. Abstract P6-10-03: The association between type-2 diabetes and risk of mortality after invasive breast cancer among Hispanic and non-Hispanic white women from New Mexico. Poster Session Abstracts. American Association for Cancer Research; 2018; 10.1158/1538-7445.sabcs17-p6-10-03
• Linoleic acid induces an increased response to insulin in MDA‐MB‐231 breast cancer cells Cite
  Rodriguez‐Monterrosas C, Diaz‐Aragon R, Cortes‐Reynosa P, Salazar EP. Linoleic acid induces an increased response to insulin in MDA‐MB‐231 breast cancer cells. Journal of Cellular Biochemistry. Wiley; 2018; 119:5413-5425 10.1002/jcb.26694
• Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study Cite
  Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, et al. Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. Oncotarget. Impact Journals, LLC; 2017; 8:115709-115717 10.18632/oncotarget.22977
• Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression Cite
  Zhang J, Li G, Chen Y, Fang L, Guan C, Bai F, et al. Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression. Journal of Cancer. Ivyspring International Publisher; 2017; 8:1849-1864 10.7150/jca.19858
• Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study Cite
  Murto M, Artama M, Pukkala E, Visvanathan K, Murtola T. Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study. International Journal of Cancer. Wiley; 2018; 142:2227-2233 10.1002/ijc.31250
• Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells Cite
  Ambrosio MR, D’Esposito V, Costa V, Liguoro D, Collina F, Cantile M, et al. Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells. Oncotarget. Impact Journals, LLC; 2017; 8:109000-109017 10.18632/oncotarget.22552
• Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production Cite
  ter Braak B, Siezen CL, Lee JS, Rao P, Voorhoeve C, Ruppin E, et al. Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0802-0
• Glucose insult elicits hyperactivation of cancer stem cells through miR-424–cdc42–prdm14 signalling axis Cite
  Nandy SB, Orozco A, Lopez-Valdez R, Roberts R, Subramani R, Arumugam A, et al. Glucose insult elicits hyperactivation of cancer stem cells through miR-424–cdc42–prdm14 signalling axis. British Journal of Cancer. Springer Science and Business Media LLC; 2017; 117:1665-1675 10.1038/bjc.2017.335
• Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System Cite
  Shao S, Gill AA, Zahm SH, Jatoi I, Shriver CD, McGlynn KA, et al. Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 27:50-57 10.1158/1055-9965.epi-17-0439
• Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes Cite
  Wu JW, Azoulay L, Majdan A, Boivin J, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3647-3653 10.1200/jco.2017.73.4491
• Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis Cite
  Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI. Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Research. American Association for Cancer Research (AACR); 2017; 77:6033-6041 10.1158/0008-5472.can-17-0687
• Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans Cite
  Wu AH, Vigen C, Butler LM, Tseng C. Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans. International Journal of Cancer. Wiley; 2017; 141:2450-2461 10.1002/ijc.31018
• High glucose levels promote the proliferation of breast cancer cells through GTPases Cite
  Hou Y, Zhou M, Xie J, Chao P, Feng Q, Wu J. High glucose levels promote the proliferation of breast cancer cells through GTPases. Breast Cancer: Targets and Therapy. Informa UK Limited; 2017; Volume 9:429-436 10.2147/bctt.s135665
• Abstract 5286: Type 2 diabetes and increased risk of estrogen receptor-negative breast cancer in African American women Cite
  Palmer JR, Castro-Webb N, Bertrand KA, Bethea TN, Rosenberg L. Abstract 5286: Type 2 diabetes and increased risk of estrogen receptor-negative breast cancer in African American women. Epidemiology. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-5286
• Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan Cite
  Yang Y, Kornelius E, Chiou J, Lai Y, Lo S, Peng C, et al. Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. Journal of Women's Health. Mary Ann Liebert Inc; 2017; 26:1278-1284 10.1089/jwh.2016.6040
• Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls Cite
  Lohmann AE, Ennis M, Taylor SK, Goodwin PJ. Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 164:451-460 10.1007/s10549-017-4263-z
• Exploring the association between diabetes and breast cancer outcomes among Latinas. Cite
  Ashing KT, Samoa R, Lai LL, Hurria A, Serrano M, Meyers E. Exploring the association between diabetes and breast cancer outcomes among Latinas.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:221-221 10.1200/jco.2017.35.5_suppl.221
• Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Cite
  Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Fumagalli D, et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1421-1429 10.1200/jco.2016.69.7722
• AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program Cite
  Wu X, Li X, Fu Q, Cao Q, Chen X, Wang M, et al. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. Journal of Experimental Medicine. Rockefeller University Press; 2017; 214:1065-1079 10.1084/jem.20160903
• Gestational diabetes mellitus may be associated with increased risk of breast cancer Cite
  Park YM, O'Brien KM, Zhao S, Weinberg CR, Baird DD, Sandler DP. Gestational diabetes mellitus may be associated with increased risk of breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2017; 116:960-963 10.1038/bjc.2017.34
• Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice Cite
  Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice. Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2017; 36 10.1186/s13046-017-0498-0
• Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women Cite
  Hong J, Jonsson Funk M, Buse JB, Henderson LM, Lund JL, Pate V, et al. Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology. Ovid Technologies (Wolters Kluwer Health); 2017; 28:446-454 10.1097/ede.0000000000000635
• Type II Diabetes, Obesity, and Breast Cancer Risk: The Multiethnic Cohort Cite
  Maskarinec G, Jacobs S, Park S, Haiman CA, Setiawan VW, Wilkens LR, et al. Type II Diabetes, Obesity, and Breast Cancer Risk: The Multiethnic Cohort. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 26:854-861 10.1158/1055-9965.epi-16-0789
• Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer Cite
  Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA. Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 26:862-868 10.1158/1055-9965.epi-16-0647
• Diabetes and Breast Cancer Subtypes Cite
  Bronsveld HK, Jensen V, Vahl P, De Bruin ML, Cornelissen S, Sanders J, et al. Diabetes and Breast Cancer Subtypes. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0170084 10.1371/journal.pone.0170084
• Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study Cite
  Jiao C, Cui L, Ma A, Li N, Si H. Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0167498 10.1371/journal.pone.0167498
• Insulin use, adipokine profiles and breast cancer prognosis Cite
  Wintrob ZA, Hammel JP, Khoury T, Nimako GK, Fu H, Fayazi ZS, et al. Insulin use, adipokine profiles and breast cancer prognosis. Cytokine. Elsevier BV; 2017; 89:45-61 10.1016/j.cyto.2016.10.017
• Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression Cite
  Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, et al. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. The Oncologist. Wiley; 2016; 21:1041-1049 10.1634/theoncologist.2015-0462
• Associations Between Maternal Pregravid Obesity and Gestational Diabetes and the Timing of Pubarche in Daughters Cite
  Kubo A, Ferrara A, Laurent CA, Windham GC, Greenspan LC, Deardorff J, et al. Associations Between Maternal Pregravid Obesity and Gestational Diabetes and the Timing of Pubarche in Daughters. American Journal of Epidemiology. Oxford University Press (OUP); 2016; 184:7-14 10.1093/aje/kww006
• Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes Cite
  Gallagher EJ, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia. Springer Science and Business Media LLC; 2016; 59:2018-2025 10.1007/s00125-016-4000-x
• Insulin glargine use and breast cancer risk: Associations with cumulative exposure Cite
  Peeters PJHL, Bazelier MT, Leufkens HGM, Auvinen A, van Staa TP, de Vries F, et al. Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta Oncologica. Informa UK Limited; 2016; 55:851-858 10.3109/0284186x.2016.1155736
• Type 2 diabetes, insulin treatment and prognosis of breast cancer Cite
  Mu L, Zhu N, Zhang J, Xing F, Li D, Wang X. Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes/Metabolism Research and Reviews. Wiley; 2016; 33:e2823 10.1002/dmrr.2823
• High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells Cite
  Flores-López LA, Martínez-Hernández MG, Viedma-Rodríguez R, Díaz-Flores M, Baiza-Gutman LA. High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells. Cellular Oncology. Springer Science and Business Media LLC; 2016; 39:365-378 10.1007/s13402-016-0282-8
• Abstract C51: Ethnic differences in the relationship between diabetes, early age adiposity, and mortality among breast cancer survivors: The Breast Cancer Health Disparities Study Cite
  Connor AE, Visvanathan K, Baumgartner KB, Baumgartner RN, Boone SD, Hines LM, et al. Abstract C51: Ethnic differences in the relationship between diabetes, early age adiposity, and mortality among breast cancer survivors: The Breast Cancer Health Disparities Study. Organ Site Research. American Association for Cancer Research; 2016; 10.1158/1538-7755.disp15-c51
• Abstract C65: Defining the implications of sugar derived metabolites (AGEs) to tamoxifen resistance and breast cancer disparity: Is it a question of lifestyle? Cite
  Walter KR, Smith DM, Phan V, spruill L, Ford ME, Findlay VJ, et al. Abstract C65: Defining the implications of sugar derived metabolites (AGEs) to tamoxifen resistance and breast cancer disparity: Is it a question of lifestyle?. Organ Site Research. American Association for Cancer Research; 2016; 10.1158/1538-7755.disp15-c65
• Effect of polyphenols on glucose and lactate transport by breast cancer cells Cite
  Martel F, Guedes M, Keating E. Effect of polyphenols on glucose and lactate transport by breast cancer cells. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:1-11 10.1007/s10549-016-3794-z
• Impact of metformin on metastases in patients with breast cancer and type 2 diabetes Cite
  Jacob L, Kostev K, Rathmann W, Kalder M. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. Journal of Diabetes and its Complications. Elsevier BV; 2016; 30:1056-1059 10.1016/j.jdiacomp.2016.04.003
• Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor Cite
  Zeng L, Zielinska HA, Arshad A, Shield JP, Bahl A, Holly JMP, et al. Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor. Endocrine-Related Cancer. Bioscientifica; 2015; 23:125-134 10.1530/erc-15-0507
• Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study Cite
  Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:709-720 10.1007/s10552-016-0744-3
• From obesity to diabetes and cancer: epidemiological links and role of therapies Cite
  García-Jiménez C, Gutiérrez-Salmerón M, Chocarro-Calvo A, García-Martinez JM, Castaño A, De la Vieja A. From obesity to diabetes and cancer: epidemiological links and role of therapies. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 114:716-722 10.1038/bjc.2016.37
• Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome Cite
  Boursi B, Giantonio BJ, Lewis JD, Haynes K, Mamtani R, Yang Y. Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. European Journal of Cancer. Elsevier BV; 2016; 59:90-98 10.1016/j.ejca.2016.02.018
• BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell Cite
  Deeney JT, Belkina AC, Shirihai OS, Corkey BE, Denis GV. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0151329 10.1371/journal.pone.0151329
• Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort Cite
  Buschard K, Thomassen K, Lynge E, Vejborg I, Tjønneland A, von Euler-Chelpin M, et al. Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 28:13-21 10.1007/s10552-016-0829-z
• High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation Cite
  Huang X, He D, Ming J, He Y, Zhou C, Ren H, et al. High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:441-455 10.1007/s10549-016-3696-0
• Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor Cite
  Zeng L, Zielinska HA, Arshad A, Shield JP, Bahl A, Holly JMP, et al. Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor. Endocrine-Related Cancer. Bioscientifica; 2015; 23:125-134 10.1530/erc-15-0507
• Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway Cite
  Kole L, Sarkar M, Deb A, Giri B. Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway. Pharmacological Reports. Springer Science and Business Media LLC; 2016; 68:144-154 10.1016/j.pharep.2015.08.001
• Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence Cite
  Bronsveld HK, ter Braak B, Karlstad Ø, Vestergaard P, Starup-Linde J, Bazelier MT, et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0611-2
• p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells Cite
  Li P, Zhao M, Parris AB, Feng X, Yang X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochemical and Biophysical Research Communications. Elsevier BV; 2015; 464:1267-1274 10.1016/j.bbrc.2015.07.117
• Prolonged Nightly Fasting and Breast Cancer Risk: Findings from NHANES (2009–2010) Cite
  Marinac CR, Natarajan L, Sears DD, Gallo LC, Hartman SJ, Arredondo E, et al. Prolonged Nightly Fasting and Breast Cancer Risk: Findings from NHANES (2009–2010). Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2015; 24:783-789 10.1158/1055-9965.epi-14-1292
• The association between diabetes and breast cancer stage at diagnosis: a population-based study Cite
  Lipscombe LL, Fischer HD, Austin PC, Fu L, Jaakkimainen RL, Ginsburg O, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:613-620 10.1007/s10549-015-3323-5
• The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes Cite
  Vissers PAJ, Cardwell CR, van de Poll-Franse LV, Young IS, Pouwer F, Murray LJ. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:427-437 10.1007/s10549-015-3331-5
• Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231 Cite
  Sharaf H, Matou-Nasri S, Wang Q, Rabhan Z, Al-Eidi H, Al Abdulrahman A, et al. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2015; 1852:429-441 10.1016/j.bbadis.2014.12.009
• Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC) Cite
  Wu AH, Kurian AW, Kwan ML, John EM, Lu Y, Keegan TH, et al. Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2014; 24:361-368 10.1158/1055-9965.epi-14-1140
• Prediabetes, Diabetes, and Risk of Breast Cancer: A Case-Control Study Cite
  Salinas-Martínez AM, Flores-Cortés LI, Cardona-Chavarría JM, Hernández-Gutiérrez B, Abundis A, Vázquez-Lara J, et al. Prediabetes, Diabetes, and Risk of Breast Cancer: A Case-Control Study. Archives of Medical Research. Elsevier BV; 2014; 45:432-438 10.1016/j.arcmed.2014.06.004
• Body mass index, diabetes, and triple-negative breast cancer prognosis Cite
  Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 146:189-197 10.1007/s10549-014-3002-y
• High Glucose Level Promotes Migration Behavior of Breast Cancer Cells through Zinc and Its Transporters Cite
  Takatani-Nakase T, Matsui C, Maeda S, Kawahara S, Takahashi K. High Glucose Level Promotes Migration Behavior of Breast Cancer Cells through Zinc and Its Transporters. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e90136 10.1371/journal.pone.0090136
• Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results Cite
  Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, et al. Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106:djt465-djt465 10.1093/jnci/djt465
• The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: Implications for cancer therapy and prevention Cite
  Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: Implications for cancer therapy and prevention. Biochimica et Biophysica Acta (BBA) - General Subjects. Elsevier BV; 2014; 1840:1943-1957 10.1016/j.bbagen.2014.01.023
• Hyperglycemia Enhances the Proliferation of Non-Tumorigenic and Malignant Mammary Epithelial Cells through Increased leptin/IGF1R Signaling and Activation of AKT/mTOR Cite
  Lopez R, Arumugam A, Joseph R, Monga K, Boopalan T, Agullo P, et al. Hyperglycemia Enhances the Proliferation of Non-Tumorigenic and Malignant Mammary Epithelial Cells through Increased leptin/IGF1R Signaling and Activation of AKT/mTOR. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e79708 10.1371/journal.pone.0079708
• Glucose promotes breast cancer aggression and reduces metformin efficacy Cite
  Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng X, Arnadottir SS, et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. Informa UK Limited; 2013; 12:3759-3769 10.4161/cc.26641
• Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity Cite
  Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity. The American Journal of Cardiology. Elsevier BV; 2013; 112:1980-1984 10.1016/j.amjcard.2013.08.026
• High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease Cite
  Minicozzi P, Berrino F, Sebastiani F, Falcini F, Vattiato R, Cioccoloni F, et al. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. European Journal of Cancer. Elsevier BV; 2013; 49:3881-3888 10.1016/j.ejca.2013.08.004
• Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients Cite
  Jiralerspong S, Kim E, Dong W, Feng L, Hortobagyi G, Giordano S. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Annals of Oncology. Elsevier BV; 2013; 24:2506-2514 10.1093/annonc/mdt224
• Association Between Metformin Therapy and Mortality After Breast Cancer: A population-based study Cite
  Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association Between Metformin Therapy and Mortality After Breast Cancer: A population-based study. Diabetes Care. American Diabetes Association; 2013; 36:3018-3026 10.2337/dc12-2535
• Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study Cite
  Contiero P, Berrino F, Tagliabue G, Mastroianni A, Di Mauro MG, Fabiano S, et al. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 138:951-959 10.1007/s10549-013-2519-9
• Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth Cite
  Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2012; 110:972-977 10.1073/pnas.1221055110
• Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies Cite
  Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies. Metabolism. Elsevier BV; 2013; 62:922-934 10.1016/j.metabol.2013.01.014
• Stressful life events and the onset of chronic diseases among Australian adults: findings from a longitudinal survey Cite
  Renzaho AMN, Houng B, Oldroyd J, Nicholson JM, D’Esposito F, Oldenburg B. Stressful life events and the onset of chronic diseases among Australian adults: findings from a longitudinal survey. European Journal of Public Health. Oxford University Press (OUP); 2013; 24:57-62 10.1093/eurpub/ckt007
• Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes Cite
  Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 137:807-816 10.1007/s10549-012-2404-y
• Diabetes, Metformin, and Breast Cancer in Postmenopausal Women Cite
  Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2844-2852 10.1200/jco.2011.39.7505
• Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial Cite
  Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2593-2600 10.1200/jco.2011.39.3769
• Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden Cite
  Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:769-777 10.1007/s10552-012-9946-5
• High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism Cite
  Steinbrenner H, Speckmann B, Pinto A, Sies H. High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. Journal of Clinical Biochemistry and Nutrition. The Society for Free Radical Research Japan; 2010; 48:40-45 10.3164/jcbn.11-002fr
• Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1 Cite
  Onken B, Driscoll M. Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS ONE. Public Library of Science (PLoS); 2010; 5:e8758 10.1371/journal.pone.0008758
• Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro Cite
  Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. Informa UK Limited; 2009; 8:909-915 10.4161/cc.8.6.7933
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) Cite
  Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®). Clinical and Translational Oncology. Springer Science and Business Media LLC; 2009; 11:455-459 10.1007/s12094-009-0384-0
• Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort Cite
  Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Annals of Oncology. Elsevier BV; 2012; 23:1838-1845 10.1093/annonc/mdr540
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer Cite
  He X, Esteva F, Ensor J, Hortobagyi G, Lee M, Yeung SJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:1771-1780 10.1093/annonc/mdr534
• Abstract C74: Eradicating cancer stem cells by targeting mTOR pathway with metformin. Cite
  Park HJ, Lee H, Williams B, Song CW. Abstract C74: Eradicating cancer stem cells by targeting mTOR pathway with metformin.. mTOR / PI3-Kinase. American Association for Cancer Research; 2011; 10.1158/1535-7163.targ-11-c74
• The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes Cite
  Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes. Elsevier BV; 2012; 6:53-59 10.1016/j.pcd.2011.10.004
• Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer Cite
  Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. Wiley; 2011; 118:1202-1211 10.1002/cncr.26439
• Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer Cite
  Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2645-2652 10.1200/jco.2010.33.4441
• Long-term effects of insulin glargine on the risk of breast cancer Cite
  Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. Springer Science and Business Media LLC; 2011; 54:2254-2262 10.1007/s00125-011-2190-9
• Fasting C-Peptide Levels and Death Resulting From All Causes and Breast Cancer: The Health, Eating, Activity, and Lifestyle Study Cite
  Irwin ML, Duggan C, Wang C, Smith AW, McTiernan A, Baumgartner RN, et al. Fasting C-Peptide Levels and Death Resulting From All Causes and Breast Cancer: The Health, Eating, Activity, and Lifestyle Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:47-53 10.1200/jco.2010.28.4752
• Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy Cite
  Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 123:333-344 10.1007/s10549-009-0647-z
• Relationship between diabetes and risk of second primary contralateral breast cancer Cite
  Li CI, Daling JR, Tang MC, Malone KE. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:545-551 10.1007/s10549-010-1035-4
• Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients. Cite
  Giordano SH, Jiralerspong S, Lopez A, Feng L, Kim ES, Gonzalez-Angulo AM, et al. Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1503-1503 10.1200/jco.2010.28.15_suppl.1503
• The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Cite
  Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:355-364 10.1007/s10549-010-0924-x
• Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer Cite
  Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer. Diabetes Care. American Diabetes Association; 2010; 33:1304-1308 10.2337/dc09-1791
• Some characteristics of familial breast cancer Cite
  Anderson DE. Some characteristics of familial breast cancer. Cancer. Wiley; 1971; 28:1500-1504 10.1002/1097-0142(197112)28:6<1500::aid-cncr2820280623>3.0.co;2-d
• Medical comorbidities predict mortality in women with a history of early stage breast cancer Cite
  Patterson RE, Flatt SW, Saquib N, Rock CL, Caan BJ, Parker BA, et al. Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 122:859-865 10.1007/s10549-010-0732-3
• Risk Factors for Male Breast Cancer?A Case-Control Study from Scandinavia Cite
  Marianne Ewertz LH. Risk Factors for Male Breast Cancer?A Case-Control Study from Scandinavia. Acta Oncologica. Informa UK Limited; 2001; 40:467-471 10.1080/02841860117406
• Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission Cite
  Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research. American Association for Cancer Research (AACR); 2009; 69:7507-7511 10.1158/0008-5472.can-09-2994
• A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer Cite
  Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, et al. A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:2046-2053 10.1158/1055-9965.epi-09-0235